Brazil Transthyretin Amyloidosis Treatment Market Size & Outlook

The transthyretin amyloidosis treatment market in Brazil is expected to reach a projected revenue of US$ 123.6 million by 2028. A compound annual growth rate of 22.4% is expected of Brazil transthyretin amyloidosis treatment market from 2022 to 2028.
Revenue, 2021 (US$M)
$30.0
Forecast, 2028 (US$M)
$123.6
CAGR, 2022 - 2028
22.4%
Report Coverage
Brazil

Brazil transthyretin amyloidosis treatment market highlights

  • The Brazil transthyretin amyloidosis treatment market generated a revenue of USD 30.0 million in 2021 and is expected to reach USD 123.6 million by 2028.
  • The Brazil market is expected to grow at a CAGR of 22.4% from 2022 to 2028.
  • In terms of segment, attr-cm was the largest revenue generating type in 2021.
  • ATTR-PN is the most lucrative type segment registering the fastest growth during the forecast period.


Transthyretin amyloidosis treatment market data book summary

Market revenue in 2021USD 30.0 million
Market revenue in 2028USD 123.6 million
Growth rate22.4% (CAGR from 2021 to 2028)
Largest segmentAttr-cm
Fastest growing segmentATTR-PN
Historical data2018 - 2020
Base year2021
Forecast period2022 - 2028
Quantitative unitsRevenue in USD million
Market segmentationATTR-PN, ATTR-CM
Key market players worldwidePfizer Inc, Johnson & Johnson, Ionis Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Astellas Pharma Inc, Prothena Corp PLC, Acrotech BioPharma, SOM Biotech


Other key industry trends

  • In terms of revenue, Brazil accounted for 0.6% of the global transthyretin amyloidosis treatment market in 2021.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
  • In Latin America, Brazil transthyretin amyloidosis treatment market is projected to lead the regional market in terms of revenue in 2028.
  • Brazil is the fastest growing regional market in Latin America and is projected to reach USD 123.6 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Transthyretin Amyloidosis Treatment Market Scope

Transthyretin Amyloidosis Treatment Market Companies

Name Profile # Employees HQ Website

Brazil transthyretin amyloidosis treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to transthyretin amyloidosis treatment market will help companies and investors design strategic landscapes.


Attr-cm was the largest segment with a revenue share of 67.33% in 2021. Horizon Databook has segmented the Brazil transthyretin amyloidosis treatment market based on attr-pn, attr-cm covering the revenue growth of each sub-segment from 2018 to 2028.


Reasons to subscribe to Brazil transthyretin amyloidosis treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Brazil transthyretin amyloidosis treatment market databook

  • Our clientele includes a mix of transthyretin amyloidosis treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Brazil transthyretin amyloidosis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Brazil transthyretin amyloidosis treatment market from 2018 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Brazil transthyretin amyloidosis treatment market size, by type, 2018-2028 (US$M)

Brazil Transthyretin Amyloidosis Treatment Market Outlook Share, 2021 & 2028 (US$M)

Brazil transthyretin amyloidosis treatment market size, by type, 2018-2028 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more